We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

January 27, 2021

This is the Future of Digital Therapeutics

Reports
HealthXL Research Team
&
Brian Dolan

Sneak peek into our upcoming report

We are excited to give you a sneak peek into our upcoming report on Prescription Digital Therapeutics. 

In 2018, we released our first report on Digital Therapeutics (DTx), aiming to get behind the hype and dig into the DTx landscape, business models, regulation, reimbursement, evidence, and adoption. In the past two years, a lot has happened. A wide variety of companies have co-opted the term “digital therapeutics” to describe their digital health offerings. This report seeks to cut through some of that noise by focusing on a smaller subset of this group: prescription digital therapeutics (PDT).

We are excited to announce that for our 2021 PDT report, we are collaborating with Brian Dolan of Exits & Outcomes (E&O). E&O is a digital health research and media company led by Brian, who also founded MobiHealthNews back in 2008. 

The objective of this HealthXL- E&O Report is to deep dive into one subsegment of DTx that has enormous potential: prescription products. We shine a light on clinical validation, adoption, investments, reimbursement and regulation. 

This report contains key examples of PDT applications, industry implications and a critical viewpoint of the current reality of the DTx environment and those which must be addressed in order to truly deliver on the DTx promise in terms of optimized health outcomes. 

What can you expect to see? 


Investment / Solutions Landscape

We examine how the investment landscape for PDTs has changed over 2018-2020.  It is clear that COVID-19 has hugely increased investments/partnerships within the digital health space, PDTs included! The top funded PDT company of 2020 was Biofourmis, obtaining a whopping $100 million in investments.

Source: Portal.HealthXL.com


Business Models and Pricing

Business models and pricing for digital therapeutics are some of the most sought after details among large corporations, investors and startups alike. In this section of the report we outline different PDT business models which include those that follow the more traditional pharmaceutical pathways to sell their products, and newly emerging models which are leveraging telemedicine to facilitate D2C access. We also take a look at the pricing of PDTs which are currently available on the market.

Clinical and Economic Outcomes

Only 27% of PDTs have published RCTs to validate their product offerings. We compare and contrast the current frameworks that support the validation of PDTs [NICE, FDA, TGA, DIGA], and dig into the rigor of evidence provided for these products vs traditional pharmaceutical agents. We also discuss the use of digital endpoints (or lack thereof) in the validation of these products.

Regulatory Environment, Reimbursement and Prescription Pathways


The report digs deep into the regulatory environment and prescription pathways for PDTs in both the US and the EU. We also assess the reimbursement landscape for PDTs across the globe - while developments in the US remain thin, the EU and Japan appear to be leading the charge in the reimbursement space. 

Source: Portal.HealthXL.com


Adoption and Enablement

Prescription capabilities remain a key challenge in the adoption of PDTs, although Germany and Belgium are spearheading change within this space. In the report we take a deep dive into the adoption and enablement of PDTs, fleshing out regional differences and highlighting companies that are shaking up the distribution chain.


The Future of PDT

PDTs are quickly emerging as one of the most spoken about areas of digital health, although it would appear that many barriers remain for the widespread adoption of these technologies. What needs to happen in politics, within the FDA, within PBMs, in the minds of physicians and consumers to move the needle? We gaze into the crystal ball.


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx-Generated RWD: What is the Value for Pharma?

27th June @ 10:45AM EDT

Real-world data (RWD) can be highly valuable to pharma companies; with several use cases from drug discovery and development to drug market access, label extensions, and understanding how their drugs and competitors are used in real life. Join this meeting to discuss this topic further with others working in this space.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx in the US

30th June @ 10:45AM EDT
Cracking the US market is no mean feat for digital health companies.
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Reimbursement of Digital Health in Europe - the DiGA framework

7th July @ 10AM EDT/ 5PM AWST

Regulatory clearance and the best commercialization model for a digital health product are among the key components for success in a rapidly growing sector. Join this Masterclass led by Flying Health to dive deeper into this topic.

Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

What Label Claims can you make about your DTx?

14th July @ 10:45AM EDT

As the Digital Therapeutics (DTx) industry matures, regulation is becoming increasingly important. Join this meeting to share your experiences with others working in this space.

Featuring
Anish Shindore
Anish Shindore
Founder & Managing Partner, GSD Health
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Featuring
Anish Shindore
Anish Shindore
Founder & Managing Partner, GSD Health
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx-Generated RWD: What is the Value for Pharma?

27th June @ 10:45AM EDT

Real-world data (RWD) can be highly valuable to pharma companies; with several use cases from drug discovery and development to drug market access, label extensions, and understanding how their drugs and competitors are used in real life. Join this meeting to discuss this topic further with others working in this space.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology

Innovation Showcase: Digital Patient Support Programs (PSPs) in Oncology

28th June @ 10:45AM EDT

Are you a Digital Health company, Pharma executive, Medtech executive, or Venture Capitalist (VC), working in Patient Support Programs (PSPs) in oncology and seeking guidance to build successful partnerships? Then keep reading, this meeting is for you

Featuring
Fiona Clemente
Fiona Clemente
Digital Health Scouting Officer, WeHealth
Jim Ternyila
Jim Ternyila
Senior Digital Health Commercialization Strategy Leader, The Janssen Pharmaceutical Companies of Johnson & Johnson
Featuring
Fiona Clemente
Fiona Clemente
Digital Health Scouting Officer, WeHealth
Jim Ternyila
Jim Ternyila
Senior Digital Health Commercialization Strategy Leader, The Janssen Pharmaceutical Companies of Johnson & Johnson
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

What’s in Remote Patient Monitoring Programs for Pharma?

29th June @ 10:45AM EDT

As the Covid-19 pandemic shifted how people interact with healthcare, the relationship between pharma and patients changed as many moved away from conventional clinical settings. Join this meeting to discuss this topic further and share your thoughts and experiences with your peers.

Featuring
Brian Flatley
Brian Flatley
VP Consulting Services at S3 Connected Health
Chris Wasden
Chris Wasden
Head of HappifyDTx, Happify Health
Featuring
Brian Flatley
Brian Flatley
VP Consulting Services at S3 Connected Health
Chris Wasden
Chris Wasden
Head of HappifyDTx, Happify Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx in the US

30th June @ 10:45AM EDT
Cracking the US market is no mean feat for digital health companies.
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.